cis -Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

Application

Cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) serves as a critical chemotherapy agent for the treatment of various cancers, including ovarian, lung, head and neck, brain, and testicular cancers, as well as neuroblastoma. As a second-generation platinum compound, similar to carboplatin, it offers enhanced therapeutic benefits while exhibiting significantly reduced nephrotoxicity, neurotoxicity, and ototoxicity compared to its precursor, cisplatin. Its mechanism involves inhibiting DNA replication by attaching alkyl groups to DNA bases, inducing cross-links, and causing nucleotide mispairing, which disrupts cell division and leads to tumor cell death. Licensed by the FDA in 1989 and available under the brand name Paraplatin, this compound has gained recognition for its ability to treat a broad spectrum of solid tumors, including those common in pediatric cases. It offers a less reactive profile due to its bidentate chelating ligand structure, ensuring lower side effects, although patients may still experience myelosuppression. With its application through intravenous administration, it remains an essential element of combination cancer therapies, showcasing its efficacy in both individualized and comprehensive oncology treatment plans.